ARTHUR STRIL

About ARTHUR STRIL

Arthur Stril currently holds a pivotal leadership role at Cellectis, a listed company focused on cell and gene therapies. Since 2025, he has served as Chief Financial Officer and Chief Business Officer, with responsibilities spanning finance, strategic business development, and investor relations. Prior to this appointment, he was named interim Chief Financial Officer in May 2024, following a steady rise within the group. He joined Cellectis in July 2018 as Vice President, Corporate Development, and was promoted to Chief Business Officer in 2020. In that role, he led business development and portfolio management activities, including the execution of strategic collaboration and investment agreements, notably with AstraZeneca. His earlier career reflects a strong blend of regulatory, public-sector, and corporate expertise. Stril began at the European Commission’s Directorate-General for Competition, where he worked on major merger-control cases in the global pharmaceutical industry. His work covered large cross-border transactions and asset swaps involving Novartis and GSK, Sanofi and Boehringer Ingelheim, as well as Pfizer’s acquisition of Hospira and Teva’s acquisition of Actavis Generics. He later joined the French Ministry of Health, where he headed the hospital financing unit and led a team responsible for a budget of roughly €80 billion. Arthur Stril holds degrees from the École Normale Supérieure in Paris and the University of Cambridge, and he also earned a diploma in immunotherapy from Paris-Descartes University. He is a member of the French Corps des Mines, which further underlines the breadth of his elite technical and administrative background. At Cellectis, he has become a key executive bridging capital markets, corporate strategy, and operational execution in a highly demanding biotechnology environment. His profile combines scientific rigor, regulatory insight, and financial leadership, making him a significant figure in the governance and strategic development of a publicly listed biotech company.